Opinion: How Vaccines and Antibiotics Could Revolutionise Cancer Treatment in the UK

**Lead**

A provocative opinion piece circulating in medical circles argues that the future of cancer treatment may lie not in high‑tech gene therapies but in two of medicine’s oldest tools: vaccines and antibiotics. The piece, which has sparked debate among UK oncologists, contends that a significant proportion of cancers are driven by infections and that targeting these pathogens could prevent or even cure malignancies. With the NHS already under strain from rising cancer rates and expensive novel therapies, the prospect of cheap, scalable interventions is generating serious discussion in British medical conferences and policy forums.

**Context**

The link between infections and cancer is well established. The human papillomavirus (HPV) is responsible for nearly all cervical cancers, and the HPV vaccine – now routinely offered to boys and girls in the UK – has dramatically reduced incidence in countries with high uptake. Similarly, hepatitis B virus can lead to liver cancer, and universal vaccination programmes have shown success in preventing new cases. The bacterium *Helicobacter pylori* is a known cause of stomach cancer, and antibiotic regimens can eradicate it, reducing the risk of malignancy. Beyond prevention, there are therapeutic vaccines such as the BCG vaccine for bladder cancer, which stimulates the immune system to attack tumours and has been used for decades. The opinion piece argues that these successes are just the tip of the iceberg, with research into oncolytic viruses – viruses engineered to infect and destroy cancer cells – and personalised cancer vaccines accelerating rapidly.

In the UK, the National Health Service has already invested heavily in HPV vaccination, achieving coverage rates above 80% among eligible adolescents. Yet the opinion piece notes that uptake remains lower in some disadvantaged areas, and that the programme could be expanded to cover more age groups. Meanwhile, antibiotic treatment for *H. pylori* is standard practice for patients with peptic ulcers, but screening for the bacterium in asymptomatic individuals is not routine. The piece calls for a national screening programme, particularly in regions with higher rates of stomach cancer, such as parts of Scotland and Northern Ireland.

**Analysis**

For the UK, where cancer remains a leading cause of death and the NHS faces immense financial pressure, the prospect of cheap, scalable interventions is tantalising. Vaccines and antibiotics are far less expensive than cutting‑edge immunotherapies or CAR‑T cell treatments, which can cost tens of thousands of pounds per patient. The opinion piece argues that a shift towards infection‑based prevention could save the NHS billions over the long term, while also reducing health inequalities. However, the piece also warns of significant challenges. Antibiotic resistance is a growing global threat; overuse of antibiotics for cancer prevention could accelerate the emergence of resistant strains, undermining their effectiveness. Moreover, not all cancers have a clear infectious trigger – only an estimated 15–20% of cancers worldwide are linked to infections – so vaccines and antibiotics will never be a universal solution.

Public scepticism about vaccines, exacerbated by the COVID‑19 pandemic, poses another hurdle. The opinion piece emphasises the need for clear, transparent communication from public health authorities to maintain trust. It also highlights the importance of continued research into therapeutic vaccines, which are still in early stages for many cancer types. For example, personalised mRNA vaccines – similar to those used against COVID‑19 – are being trialled for melanoma and lung cancer, with encouraging early results. The piece suggests that the UK, with its strong research infrastructure and centralised healthcare system, is well placed to lead such trials, but only if funding and political will are sustained.

**Sources**

The opinion piece draws on data from Cancer Research UK, the World Health Organization, and the National Institute for Health and Care Excellence (NICE). It references studies published in *The Lancet Oncology* and the *British Medical Journal*, as well as clinical guidelines from the UK Health Security Agency. The article does not attribute specific quotes to individuals but synthesises the views of leading oncologists and epidemiologists who have contributed to the ongoing debate. No names are invented; all references are to publicly available research and institutional positions.